奥比塞特拉皮布是CETP抑制剂的重生吗?
Bliss Chang1, Luke J Laffin2,3, Ashish Sarraju2,3
1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Current atherosclerosis reports
|August 16, 2024
概括
作为胆固醇转移蛋白 (CETP) 抑制剂的obicetrapib在降低LDL-C和其他脂质方面表现有前途. 目前正在进行的试验将确定其在治疗脱脂症和动脉样硬化心血管疾病 (ASCVD) 中的作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 脂质学 脂质学是指脂质学.
背景情况:
- 脱脂症和动脉样硬化心血管疾病 (ASCVD) 仍然是严重的健康问题.
- 胆固醇转移蛋白 (CETP) 抑制剂代表了脂质修饰的治疗标.
- 奥比塞特拉皮布是一种正在研究的第三代CETP抑制剂.
研究的目的:
- 审查obicetrapib的发展状态.
- 讨论obicetrapib在治疗失脂症和ASCVD中的潜在作用.
- 为新出现的临床试验数据提供视角.
主要方法:
- 对II期临床试验数据 (ROSE和ROSE2试验) 的审查.
- 对obicetrapib对脂质生物标志物影响的分析.
- 目前正在进行的第三期临床试验的概述,包括心血管结局试验.
主要成果:
- 奥比塞特拉皮显著降低低密度脂蛋白胆固醇 (LDL-C),阿波蛋白B (Apo B) 和非高密度脂蛋白胆固醇 (非HDL-C).
- 奥比塞特拉皮布显示了高密度脂蛋白胆固醇 (HDL-C) 的增加.
- 早期研究的初步安全数据显示,没有显著的安全问题.
结论:
- 奥比塞特拉皮布对关键的失脂血症生物标志物表现出有利的影响.
- 该药物有可能减少ASCVD事件.
- 需要在III期试验中进行进一步评估,以确认疗效和安全性.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
604
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
604
01:39Receptor-mediated Endocytosis
104.2K
Overview
104.2K
01:21Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149
01:45ER Retrieval Pathway
3.8K
In the secretory pathway, vesicles transport proteins from one cellular compartment to another in forward transport to deliver the protein to its correct location. Occasionally, misfolded proteins and incorrect proteins escape their original compartments, and a retrieval pathway is used to return the escaped proteins to their original compartment.
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
3.8K